With respect to clinicopathologic features, our study showed that KRAS mutations in exon 2/3 were associated with a high rate of positive extranodal tumor deposit, and extranodal tumor deposit was known as a predictor of poor prognosis 17, 18. The gene discussed is KRAS; the disease is neoplasm.